Sign In
Buy IGC
$0.268
+0.0079 (+3.04%)
At Close: Jul 20, 2026
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
09:00am, Thursday, 20'th Mar 2025
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the ad
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
09:00am, Monday, 17'th Mar 2025
POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's
POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage repo
POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
09:00am, Tuesday, 04'th Mar 2025
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the dev
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
09:00am, Thursday, 20'th Feb 2025
- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:I
IGC Pharma Reports Third Quarter Fiscal 2025 Results
08:30am, Tuesday, 18'th Feb 2025
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates
06:11pm, Friday, 14'th Feb 2025
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
08:30am, Tuesday, 11'th Feb 2025
- Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:06pm, Tuesday, 28'th Jan 2025
IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
08:30am, Tuesday, 28'th Jan 2025
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
08:30am, Monday, 13'th Jan 2025
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fir
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
08:30am, Wednesday, 08'th Jan 2025
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced to
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
07:00pm, Thursday, 19'th Dec 2024
POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock
01:01pm, Wednesday, 18'th Dec 2024
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
